Sign in

    Dennis Cho

    Research Analyst at Jefferies

    Dennis Cho is an experienced Equity Research Analyst at Jefferies, specializing in coverage of U.S. consumer, retail, and restaurant companies. Known for his deep analysis of publicly traded firms such as Shake Shack, Wingstop, and Restaurant Brands International, Cho has developed a strong reputation for actionable investment recommendations and consistent coverage accuracy. He began his finance career in the early 2010s, joining Jefferies after holding prior roles at other financial institutions focused on equity analysis. He holds key industry credentials, including Series 7 and 63 securities licenses, and is registered with FINRA, which further underpins his expertise and trustworthiness as a research professional.

    Dennis Cho's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

    Dennis Cho's questions to RECURSION PHARMACEUTICALS (RXRX) leadership • Q2 2025

    Question

    Dennis from Jefferies asked about the CDK7 combination expansion cohort in ovarian cancer, specifically the standard of care being allowed and the efficacy benchmarks for ORR and PFS.

    Answer

    Chief R&D and Commercial Officer Najat Khan stated the standard of care will include single-agent chemo plus bevacizumab (beva). She noted the median PFS for that combination is around 6.7 months, and Recursion aims for a meaningful improvement. She also mentioned the team will assess other critical endpoints.

    Ask Fintool Equity Research AI